Threshold Pharmaceuticals’ (THLD) Outperform Rating Reiterated at William Blair
Separately, S&P Equity Research dropped their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a research report on Friday, September 30th.
Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.5889 on Monday. Threshold Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $4.44. The firm has a market cap of $42.11 million, a price-to-earnings ratio of 0.9948 and a beta of 3.97. The company’s 50-day moving average price is $1.05 and its 200 day moving average price is $0.62.
Threshold Pharmaceuticals (NASDAQ:THLD) last issued its quarterly earnings data on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). On average, equities analysts expect that Threshold Pharmaceuticals will post ($0.38) earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in THLD. First Eagle Investment Management LLC bought a new position in Threshold Pharmaceuticals during the second quarter valued at $2,033,000. Adage Capital Partners GP L.L.C. increased its position in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 500,000 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock worth $468,000 after buying an additional 363,100 shares in the last quarter. Oxford Asset Management increased its stake in shares of Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock worth $129,000 after buying an additional 178,602 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of Threshold Pharmaceuticals during the second quarter worth approximately $152,000. 28.22% of the stock is owned by institutional investors.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.